Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QL00 | ISIN: US28617K1016 | Ticker-Symbol: 2TK
Frankfurt
05.09.25 | 08:15
2,180 Euro
+0,93 % +0,020
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ELEDON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ELEDON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,2802,36019:02
2,2002,40005.09.

Aktuelle News zur ELEDON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.08.Eledon Pharmaceuticals GAAP EPS of -$0.131
14.08.Eledon Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
14.08.Eledon Pharmaceuticals, Inc. - 10-Q/A, Quarterly Report1
14.08.Eledon Pharmaceuticals, Inc. - 10-K/A, Annual Report1
14.08.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results164Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline...
► Artikel lesen
06.08.Eledon Pharmaceuticals, Inc.: Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation72Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function...
► Artikel lesen
30.07.Eledon to host conference call on kidney transplant study results3
ELEDON PHARMACEUTICALS Aktie jetzt für 0€ handeln
10.07.Cantor Fitzgerald reiterates Overweight rating on Eledon Pharmaceuticals stock6
10.07.Sernova Biotherapeutics Inc: Sernova signs research deal with Eledon Pharma141
09.07.Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes983LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals...
► Artikel lesen
26.06.Eledon stock rating reiterated as Overweight by Cantor Fitzgerald2
25.06.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City4
18.06.H.C. Wainwright assumes coverage on Eledon stock with buy rating1
12.06.Eledon Pharmaceuticals, Inc. - 8-K, Current Report2
15.05.Cantor Fitzgerald maintains Overweight on Eledon Pharmaceuticals stock2
15.05.Eledon Pharmaceuticals GAAP EPS of -$0.081
14.05.Eledon Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
14.05.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results154On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant...
► Artikel lesen
07.04.Eledon Pharmaceuticals, Inc. - 8-K, Current Report1
20.03.Eledon Pharmaceuticals, Inc. - 10-K, Annual Report1
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1